The prevalence and frequency of menstrual cycle symptoms are associated with women’s availability to train and compete: A study of 6,812 exercising women recruited using the STRAVA™ exercise app

Objectives: The menstrual cycle can affect sports participation and exercise performance. There are very few data on the specific menstrual cycle symptoms (symptoms during various phases of the cycle, not only during menstruation) experienced by exercising women. We aimed to characterise the most common symptoms; the number and frequency of symptoms; and we evaluated whether menstrual cycle symptoms were associated with sporting outcomes. Methods: 6,812 adult women of reproductive age (mean age: 38.3 (8.7) years) who were not using combined hormonal contraception were recruited via the STRAVA exercise app user database and completed a 39-part survey. Respondents were from seven geographical areas, and questions were translated and localised to each region (Brazil, n=1,288; France, n=1,911; Germany, n=1,178; Spain, n=1,204; UK & Ireland, n=2,311; and USA, n=2,479). The survey captured exercise behaviours; current menstrual status; the presence and frequency of menstrual cycle symptoms; medication use for symptoms; perceived effects of the menstrual cycle on exercise and work behaviours; and history of hormonal contraception use. We propose a novel Menstrual Symptom index (MSi) based on the presence and frequency of 18 commonly reported symptoms (range 0-54 where 54 would be all 18 symptoms each occurring very frequently). Results: The most prevalent menstrual cycle symptoms were mood changes/anxiety (90.6%), tiredness/fatigue (86.2%), stomach cramps (84.2%), and breast pain/tenderness (83.1%). After controlling for BMI, training volume and age, the Menstrual Symptom Index was associated with a greater likelihood of missing or changing training (OR= 1.09 (CI: 1.08,1.10); p<0.05), missing a sporting event/competition (OR= 1.07 (CI: 1.06,1.08); p=<0.05), absenteeism from work/academia (OR= 1.08 (CI: 1.07,1.09); p=<0.05), and use of pain medication (OR= 1.09 (CI: 1.08,1.09); p=